Although the first results of the clinical trials with compounds that target insulin/IGF signaling in PDAC have been disappointing, researchers have recently directed their research towards understanding the role of Insulin/IGF-1R signaling in the cross-talk between cancer cells and stroma. This evidence concerns the gene IGF1 and cancer.